{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"VALOR","nct_id":"NCT02984761","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=valor-nct02984761. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"VALOR","arms":[{"description":"Stereotactic radiotherapy is an FDA approved treatment for lung cancer. However, for purposes of this study, it is being delivered to an operable population that is typically treated with surgical resection. Participants randomized to stereotactic radiotherapy will be treated according to the location of the tumor. Peripheral tumors will receive either 18 Gy x 3, 14 Gy x 4, or 11.5 Gy x 5 fractions, while central tumors will be treated with 10 Gy x 5. There will not be any elective coverage of local microscopic spread or regional lymph nodes.","label":"Stereotactic radiotherapy","type":"EXPERIMENTAL"},{"description":"Participants randomized to surgery will undergo a standard lobectomy or limited anatomic pulmonary resection (segmentectomy) under general anesthesia. Non-anatomic (wedge) resections are not permitted. Pathological specimens must contain a separately divided pulmonary artery and bronchus, as well as sampled lymph nodes from mediastinal lymph node stations. Participants found to have incidental nodal involvement after surgery will be referred for adjuvant chemotherapy, with our without postoperative radiotherapy.","label":"Surgery","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2034-03-31","type":"ESTIMATED"},"conditions":["Lung Neoplasm"],"enrollment":{"count":670,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Stereotactic Radiotherapy","otherNames":["Stereotactic Body Radiation Therapy (SBRT) or Stereotactic Ablative Radiotherapy (SAbR)"],"type":"RADIATION"},{"name":"Anatomic Pulmonary Resection","otherNames":["Lobectomy or Anatomic Segmentectomy"],"type":"PROCEDURE"}],"last_update":"2026-10-23","lead_sponsor":"VA Office of Research and Development","official_title":"CSP #2005 - Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy Trial (VALOR)","overall_status":"RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2032-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"From date of randomization through study completion, up to 10 years"}],"references":[{"citation":"Moghanaki D, Karas T, Timmerman RD, Cameron RB, Ritter TA, Shi H, Leiner MK, Feng H, Skinner VL, Robin L, Odle C, Sindowski T, Snodgrass AJ, Huang GD, Reda DJ, Harpole DH; Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy Study Team. Protocol for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer. CHEST Pulm. 2023 Oct 5;1(3):100024. doi: 10.1016/j.chpulm.2023.100024. eCollection 2023 Dec.","pmid":"42548402","type":"DERIVED"},{"citation":"Elbanna M, Shiue K, Edwards D, Cerra-Franco A, Agrawal N, Hinton J, Mereniuk T, Huang C, Ryan JL, Smith J, Aaron VD, Burney H, Zang Y, Holmes J, Langer M, Zellars R, Lautenschlaeger T. Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy. Clin Lung Cancer. 2021 May;22(3):e342-e359. doi: 10.1016/j.cllc.2020.05.024. Epub 2020 Jun 2.","pmid":"32736936","type":"DERIVED"}],"start_date":{"date":"2017-04-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy","url":"https://clinicaltrials.gov/study/NCT02984761"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/valor-nct02984761"}